Merck & Company Inc (MRK)

Conclusion

Merck & Co. develops and sells human health pharmaceuticals and vaccines, including Keytruda, Gardasil and Januvia, and also runs an animal health business. At a price of 148.76 USD, the company has a market capitalisation of 366.7 billion USD.

The verdict is overvalued. The price stands at 149.5 times earnings against a ten-year median of 23.9, and at 31.5 times EV/EBITDA against a median of 14.0. The fair value band runs from 96.21 to 144.32 USD with a midpoint of 120.26 USD, a margin of safety of -19.2% at the current price. The DCF gives 131.45 USD per share, and the fair value from historical multiples is 109.08 USD. The reverse DCF implies growth of 9.2% a year, against revenue growth of 9.4% over five years and free cash flow per share growth of 17.6% over the same period.

The strongest numbers are an Altman Z-score of 3.96, in the safe zone, a five-year free cash flow conversion of 101.1%, and eight earnings beats in eight quarters. The weakest are a ROIC of 6.1% against a WACC of 8.3%, net debt to EBITDA of 3.39, and next-year EPS estimates cut by 6.2% over 90 days, with 17 downward revisions and no upward revisions in the last 30 days.

Financial health

Financial strength is green, held up by a safe Altman Z-score and a current ratio of 1.35, and held back only by leverage. The quick ratio is 0.78, net debt to EBITDA is 3.39 and interest coverage is 3.18, both assessed as neutral. Debt to equity stands at 1.20. The Altman Z-score of 3.96 sits in the safe zone. That model was designed mainly for manufacturers, and Merck is classed as a drug manufacturer, so the reading applies. Insolvency risk: low, about 0.2% by the estimate of the Ohlson model over one to two years.

Earnings quality

Earnings quality is green, with three of four assessed signals good. Free cash flow conversion is 601.1% on a trailing basis and 101.1% over five years, so the trailing figure is far above the long-run norm and should not be extrapolated. The accrual ratio is 1.4%. Stock-based compensation is 1.6% of revenue, and free cash flow after it is 13.69 billion USD. The share count fell at a compound rate of 0.3% over five years, which reflects buybacks. The Piotroski score is 4 of 9. The Beneish M-score of -2.19 is read as unlikely to indicate manipulation. Merck beat estimates in all eight recent quarters, with an average surprise of 13.1%. Current-year EPS estimates rose 0.9% over 90 days, but 15 analysts cut them in the last 30 days against two raising them.

Profitability

Profitability is yellow: the operating margin is assessed good, while ROIC is assessed bad. The gross margin is 77.0% against a ten-year median of 70.0%. The operating margin is 16.2% against a median of 20.7%, and the trailing net margin is 3.6% against a median of 20.8%. Margin stability over the year is 42.9%. The ROIC is 6.1% against a WACC of 8.3%, a ROIC minus WACC of -2.2%, which destroys value. The five-year median ROIC was 22.0%, so returns have fallen sharply. The return on equity is 5.5%. The DuPont split for 2025 shows a net margin of 28.1%, an asset turnover of 0.47 and an equity multiplier of 2.60, so leverage is not what lifts the return on equity.

Growth

Growth is green, with all four assessed signals good. Revenue grew at a compound rate of 3.1% over three years, 9.4% over five and 5.1% over ten. Earnings per share grew 8.4% over three years, 21.2% over five and 16.6% over ten. Free cash flow per share fell 5.2% over three years, but grew 17.6% over five and 2.2% over ten. Revenue rose in nine of ten comparable years. The next-year EPS growth field reads 224.7%, far above any rate delivered in the past, and the input does not explain it, so it should not be relied on.

Valuation

Valuation is red, with the verdict assessed as bad. Against their ten-year medians, the current multiples carry premiums: price to earnings 149.5 against 23.9 (premium of 525.8%), EV/EBITDA 31.5 against 14.0 (125.8%), price to free cash flow 24.9 against 23.0 (7.9%), price to sales 5.4 against 4.7 (16.9%) and price to book 8.2 against 6.0 (36.4%). The DCF gives 131.45 USD per share, using a discount rate of 8.87%, first-stage growth of 9.35% and terminal growth of 2.5%. The terminal value makes up 58.6% of that value. The reverse DCF implies growth of 9.2%, against revenue growth of 9.4% over five years and free cash flow per share growth of 17.6%. The fair value band is an order-of-magnitude estimate built on fixed assumptions, including a 5% equity risk premium, and is not a price target. The dividend yield is 2.3%, the forward yield 2.3%, and the payout on free cash flow 56.7%.

Risks

The ROIC of 6.1% against a WACC of 8.3% is the most serious weakness: new investment is currently earning less than its cost of capital. Net debt to EBITDA of 3.39 and interest coverage of 3.18 mean that a fall in earnings would leave less room to service debt. Falling estimates, with 17 downward revisions for next year and none upward in the last 30 days, could erode the earnings base that the price depends on. The trailing free cash flow conversion of 601.1% is far from the five-year figure, which makes the current cash flow harder to read. The DCF rests on a terminal value share of 58.6%, so small changes in long-run assumptions move the result. The analysis does not include a debt maturity schedule or revenue by segment, so refinancing risk and the contribution of individual drugs cannot be assessed. The next-year growth figure is unexplained and is not relied on here.